share_log

Purple Biotech Says Randomized Phase 2 CM24 Pancreatic Cancer Study Selected As Late-Breaking Abstract Poster Presentation At ASCO 2024 Annual Meeting

Purple Biotech Says Randomized Phase 2 CM24 Pancreatic Cancer Study Selected As Late-Breaking Abstract Poster Presentation At ASCO 2024 Annual Meeting

Purple Biotech表示，隨機2期CM24胰腺癌研究在ASCO 2024年年會上被選爲最新摘要海報演講
Benzinga ·  04/25 19:25

Purple Biotech Says Randomized Phase 2 CM24 Pancreatic Cancer Study Selected As Late-Breaking Abstract Poster Presentation At ASCO 2024 Annual Meeting

Purple Biotech表示，隨機2期CM24胰腺癌研究在ASCO 2024年年會上被選爲最新摘要海報演講

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論